title: [Secondary prevention with antiplatelet therapy in cardiac rehabilitation].
abstract: The long-term increased cardiovascular risk of patients with an acute coronary syndrome (ACS) is a challenging and common clinical problem. Recent evidence demonstrated an ischemic benefit for a prolonged dual antiplatelet therapy beyond the initial 12 months at the cost of an increased bleeding risk. Individual, careful and repeated risk-benefit analyses are essential for an optimized patient management in which cardiovascular rehabilitation providers may play a central role.
authors.affiliation: Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich.
authors.forename: Maria M
authors.initials: MM
authors.lastname: Wanitschek
authors.affiliation: Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. hannes.alber@i-med.ac.at.|Department Kardiologie, Reha-Zentrum Münster, Gröben 700, 6232, Münster, Österreich. hannes.alber@i-med.ac.at.|Karl Landsteiner Institut für interdisziplinäre Forschung, Reha Zentrum Münster in Tirol, 6232, Münster, Österreich. hannes.alber@i-med.ac.at.
authors.forename: Hannes F
authors.initials: HF
authors.lastname: Alber
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000150:complications; D000072038:Cardiac Rehabilitation; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D018570:Risk Assessment; D055502:Secondary Prevention
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: acute coronary syndrome; dual antiplatelet therapy; long-term; prolonged; myocardial infarction; rehabilitation program; secondary prevention